Allergic rhinitis
Conditions
Interventions
placebo group:placebo
Sponsors
China Agricultural University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years; 2. No less than 2 clinical symptoms such as sneezing, runny nose, nasal congestion and itching occurred without taking drugs, and the symptoms lasted for more than 1 hour every day; 3. Persistent rhinitis symptoms for at least 1 year; 4. At least one of the following two conditions shall be met: at least one of the following five common allergen skin prick tests is positive (the average diameter of the wind mass >= 3 mm): house dust (Dp), house dust mites (Df), cats, dogs and cockroaches; Or specific IgE detection (Pharmacia CAP system >= 3.5 Ku/L); 5. Volunteer to participate in the test and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Suffering from mental disease, gastrointestinal disease, heart, liver, kidney, hematopoietic system or immune system and other serious diseases; 2. Patients diagnosed with other allergic diseases (such as dermatitis and asthma) except allergic rhinitis; 3. Patients with upper respiratory tract infection or sinusitis or nasal polyps; 4. Currently in pregnancy or lactation; 5. Patients who have received immunotherapy or regularly taken anti-inflammatory drugs (such as aspirin, paracetamol, etc.); 6. Those who have used probiotics, antibiotics (such as cephalosporin, levofloxacin, etc.), proton pump inhibitors (PPI, such as omeprazole, lansoprazole, pantoprazole, rabeprazole, etc.), H2 receptor antagonists (such as cimetidine, ranitidine, etc.), laxatives, and antibacterial agents (such as berberine) within 4 weeks before the start of the study; 7. Patients who had used antihistamines or nasal spray of glucocorticoids within one week before the start of the study, or had used oral glucocorticoids 3 months before the study; 8. Other clinicians consider it inappropriate to participate in this trial, as well as patients participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total score of nasal symptoms;Rhinitis Control Assessment Test;IgE antibodies; | — |
Secondary
| Measure | Time frame |
|---|---|
| Nose eosinophil count;Intestinal metabolites;gut flora;Assessment of quality of life in allergic rhinitis;Immune cells;Inflammatory cytokines; | — |
Countries
China
Contacts
Public ContactJingjing He
China Agricultural University
Outcome results
None listed